NeuroPace (NASDAQ:NPCE) Cut to “Market Perform” at Leerink Partners

Leerink Partners downgraded shares of NeuroPace (NASDAQ:NPCE – Free Report) from an outperform rating to a market perform rating in a report released on Friday morning, Marketbeat reports. Leerink Partners currently has $7.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Mizuho assumed coverage on NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective on the stock. Raymond James Financial set a $21.00 price objective on NeuroPace in a report on Tuesday, September 15th. KeyCorp initiated coverage on NeuroPace in a research note on Thursday, September 17th. They set an “overweight” rating and a $18.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a report on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.50.

Read Our Latest Research Report on NPCE

NeuroPace Price Performance

NASDAQ NPCE opened at $7.56 on Friday. NeuroPace has a 12 month low of $5.46 and a 12 month high of $19.60. The firm has a market capitalization of $259.46 million, a PE ratio of -13.50 and a beta of 1.98. The company’s 50 day simple moving average is $13.21 and its 200 day simple moving average is $14.75. The company has a debt-to-equity ratio of 5.15, a current ratio of 5.26 and a quick ratio of 4.09.

Institutional Trading of NeuroPace

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of NeuroPace during the second quarter valued at $39,369,000. First Light Asset Management LLC boosted its position in shares of NeuroPace by 82.3% in the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares during the period. Deutsche Bank AG purchased a new position in NeuroPace in the 2nd quarter worth about $14,919,000. GSA Capital Partners LLP purchased a new position in NeuroPace in the 2nd quarter worth about $1,836,000. Finally, Man Group plc purchased a new position in NeuroPace in the 2nd quarter worth about $1,336,000. 78.83% of the stock is currently owned by institutional investors.

NeuroPace News Summary

These are some of the NPCE news items that stood out recently:

  • Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
  • Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
  • Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes

About NeuroPace

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Featured Articles

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.